Vaxcyte reported that its 31-valent pneumococcal conjugate vaccine, VAX-31, met key primary immunogenicity endpoints in a Phase 3 trial in adults 50 and older, triggering a sharp market reaction. The program positions the company to compete in a crowded pneumococcal market where coverage and immune response durability drive uptake and payer value.